We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





Distinct Blood Signatures Found in COVID-19 Patients Could Significantly Improve Testing

By LabMedica International staff writers
Posted on 13 Jan 2021
Researchers have discovered distinct blood signatures present in patients with COVID-19 that could significantly improve testing and long-term monitoring of the disease.

The research team at the Australian National Phenome Centre (ANPC) at Murdoch University (Perth, Australia) applied advanced analytical chemistry methods to study the plasma of patients suffering from COVID-19 infection and found diagnostic markers that were not present in respiratory patients that tested negative for the virus. More...
Specifically, the research found that plasma lipoproteins – structures that transport fats around the body – in the blood of COVID-19 patients had changed dramatically during infection. They became closer to patterns typically found in patients with diabetes, atherosclerosis and cardiovascular disease.

The study involved the analysis of blood plasma samples collected from patients who presented COVID-19 disease symptoms and subsequently tested positive; healthy adults who had not exhibited COVID-19 disease symptoms; and patients with COVID-19 disease symptoms who tested negative. The samples were analyzed using state-of-the-art metabolic phenotyping technologies, which can reveal the molecular structures and quantitative bioanalysis for almost any type of biological liquid or solid. The analysis provided the unique biological ‘fingerprints’ of each sample, on which the research findings were based. The researchers believe that their work underlines the importance of long-term follow up studies on “recovered” COVID-19 patients, particularly those experiencing persistent effects, to assess their health status and take steps to mitigate any long-term effects of COVID-19 exposure.

“This work opens the door to a new type of test that does not depend on detection of the virus itself but that can help discriminate COVID-19 infections, especially when used in conjunction with conventional PCR testing,” explained Professor Jeremy Nicholson, Director of the ANPC and leader of the research. “This would increase the overall security of existing testing procedures, such as those used in quarantine situations, which may be key to future easing of State and National lock-down protocols especially with the advent of the new UK B.1.1.7 corona virus variant which is significantly more infectious and affects children more easily.”

Related Links:
Murdoch University


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.